Shumei Kato

Title(s)Associate Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Websites

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Toll-like receptor 3: a double-edged sword. Biomark Res. 2025 Feb 23; 13(1):32. Hsieh ML, Nishizaki D, Adashek JJ, Kato S, Kurzrock R. PMID: 39988665; PMCID: PMC11849352.
      View in: PubMed   Mentions:
    2. Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders. Cytokine Growth Factor Rev. 2025 Jan 23. Saran A, Nishizaki D, Lippman SM, Kato S, Kurzrock R. PMID: 39875232.
      View in: PubMed   Mentions:    Fields:    
    3. Novel clinical trial designs emerging from the molecular reclassification of cancer. CA Cancer J Clin. 2025 Jan 22. Nikanjam M, Kato S, Allen T, Sicklick JK, Kurzrock R. PMID: 39841128.
      View in: PubMed   Mentions:    Fields:    
    4. Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations. J Clin Oncol. 2025 Feb 20; 43(6):705-715. Weitz J, Nishizaki D, Liau J, Patel J, Ng I, Sun S, Ramms D, Zou J, Wishart B, Rull J, Baumgartner J, Kelly K, White R, Veerapong J, Hosseini M, Patel H, Botta G, Gutkind JS, Tiriac H, Kato S, Lowy AM. PMID: 39413348; PMCID: PMC11829827.
      View in: PubMed   Mentions:    Fields:    
    5. Tumor necrosis factor superfamily signaling: life and death in cancer. Cancer Metastasis Rev. 2024 Dec; 43(4):1137-1163. Ababneh O, Nishizaki D, Kato S, Kurzrock R. PMID: 39363128; PMCID: PMC11554763.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    6. 4-1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4-1BB agonists. Cancer Commun (Lond). 2024 Oct; 44(10):1168-1172. Uehara Y, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Pabla S, Conroy JM, DePietro P, Ko H, Sicklick JK, Kurzrock R. PMID: 39097973; PMCID: PMC11483270.
      View in: PubMed   Mentions:    Fields:    
    7. Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy. iScience. 2024 Aug 16; 27(8):110465. Louie BH, Kato S, Lim JS, Kim KH, Lim HJ, Okamura R, Lee S, Kim L, Sicklick JK, Lippman SM, Kurzrock R. PMID: 39148716; PMCID: PMC11324991.
      View in: PubMed   Mentions:
    8. TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer. Am J Cancer Res. 2024; 14(5):2493-2506. Ahmed J, Nishizaki D, Miyashita H, Lee S, Nesline MK, Pabla S, Conroy JM, DePietro P, Sicklick JK, Kato S, Kurzrock R. PMID: 38859842; PMCID: PMC11162668.
      View in: PubMed   Mentions:
    9. The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types. Am J Cancer Res. 2024; 14(5):2240-2252. Miyashita H, Bevins NJ, Thangathurai K, Lee S, Pabla S, Nesline MK, Glenn ST, Conroy JM, DePietro P, Rubin E, Sicklick JK, Kato S, Kurzrock R. PMID: 38859855; PMCID: PMC11162686.
      View in: PubMed   Mentions: 1  
    10. Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses. Med. 2024 Jul 12; 5(7):689-717. Nikanjam M, Wells K, Kato S, Adashek JJ, Block S, Kurzrock R. PMID: 38749442; PMCID: PMC11246816.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. KRAS G12C inhibitor combination therapies: current evidence and challenge. Front Oncol. 2024; 14:1380584. Miyashita H, Kato S, Hong DS. PMID: 38756650; PMCID: PMC11097198.
      View in: PubMed   Mentions: 4  
    12. A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer Res Commun. 2024 04 30; 4(4):1165-1173. Garmezy B, Borad MJ, Bahleda R, Perez CA, Chen LT, Kato S, Oh DY, Severson P, Tam BY, Quah CS, Harding JJ. PMID: 38602417; PMCID: PMC11060137.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    13. Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer. Int J Mol Sci. 2024 Apr 26; 25(9). Shreenivas A, Nishizaki D, Lee S, Pabla S, Nesline M, Conroy JM, DePietro P, Kato S, Kurzrock R. PMID: 38731962; PMCID: PMC11083822.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    14. Transcriptomic analysis of GITR and GITR ligand reveals cancer immune heterogeneity with implications for GITR targeting. Am J Cancer Res. 2024; 14(4):1634-1648. Moussa P, Kurzrock R, Nishizaki D, Miyashita H, Lee S, Nikanjam M, Pabla S, Nesline MK, Ko H, Conroy JM, DePietro P, Sicklick JK, Kato S. PMID: 38726288; PMCID: PMC11076267.
      View in: PubMed   Mentions: 2  
    15. High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy. iScience. 2024 Apr 19; 27(4):109632. Fujiwara Y, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Conroy JM, DePietro P, Pabla S, Lippman SM, Kurzrock R. PMID: 38632994; PMCID: PMC11022045.
      View in: PubMed   Mentions:
    16. OX40/OX40 ligand and its role in precision immune oncology. Cancer Metastasis Rev. 2024 Sep; 43(3):1001-1013. Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Previs RA, Conroy JM, DePietro P, Pabla S, Kurzrock R. PMID: 38526805; PMCID: PMC11300540.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    17. If it's a target, it's a pan-cancer target: Tissue is not the issue. Cancer Treat Rev. 2024 Apr; 125:102721. Adashek JJ, Kato S, Sicklick JK, Lippman SM, Kurzrock R. PMID: 38522181; PMCID: PMC11093268.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer. BMC Med. 2024 02 19; 22(1):74. Adashek JJ, Pandya C, Maragakis NJ, De P, Cohen PR, Kato S, Kurzrock R. PMID: 38369520; PMCID: PMC10875826.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    19. LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes. Am J Cancer Res. 2024; 14(1):368-377. Adashek JJ, Kato S, Nishizaki D, Pabla S, Nesline MK, Previs RA, Conroy JM, DePietro P, Kurzrock R. PMID: 38323282; PMCID: PMC10839320.
      View in: PubMed   Mentions: 1  
    20. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Ther Adv Med Oncol. 2024; 16:17588359231220510. Krishnamurthy N, Nishizaki D, Lippman SM, Miyashita H, Nesline MK, Pabla S, Conroy JM, DePietro P, Kato S, Kurzrock R. PMID: 38188465; PMCID: PMC10771755.
      View in: PubMed   Mentions: 2  
    21. Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. Cancer Med. 2024 Jan; 13(1):e6844. Lim J, Kurzrock R, Nishizaki D, Miyashita H, Adashek JJ, Lee S, Pabla S, Nesline M, Conroy JM, DePietro P, Lippman SM, Kato S. PMID: 38132831; PMCID: PMC10807558.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    22. Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards. Surg Oncol Clin N Am. 2024 Apr; 33(2):197-216. Fujiwara Y, Kato S, Kurzrock R. PMID: 38401905; PMCID: PMC10894322.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Considering molecular alterations as pan-cancer tissue-agnostic targets. Nat Cancer. 2023 Dec; 4(12):1622-1626. Adashek JJ, Kato S, Sicklick JK, Lippman SM, Kurzrock R. PMID: 38102355; PMCID: PMC11262846.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    24. Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown. Mol Oncol. 2024 Apr; 18(4):956-968. Kato S, Gumas S, Adashek JJ, Okamura R, Lee S, Sicklick JK, Kurzrock R. PMID: 35866362; PMCID: PMC10994241.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    25. Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy. Mol Cancer Ther. 2023 Nov 01; 22(11):1352-1362. Jou J, Kato S, Miyashita H, Thangathurai K, Pabla S, DePietro P, Nesline MK, Conroy JM, Rubin E, Eskander RN, Kurzrock R. PMID: 37619986; PMCID: PMC11347188.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol. 2023 Sep 29; 7(1):101. Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R. PMID: 37773318; PMCID: PMC10542332.
      View in: PubMed   Mentions: 11  
    27. At the right dose: personalised (N-of-1) dosing for precision oncology. Eur J Cancer. 2023 11; 194:113359. Nikanjam M, Kato S, Sicklick JK, Kurzrock R. PMID: 37832506.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy. NPJ Genom Med. 2023 Aug 08; 8(1):19. Miyashita H, Kurzrock R, Bevins NJ, Thangathurai K, Lee S, Pabla S, Nesline M, Glenn ST, Conroy JM, DePietro P, Rubin E, Sicklick JK, Kato S. PMID: 37553332; PMCID: PMC10409760.
      View in: PubMed   Mentions: 8  
    29. Challenges and prospects of CSF1R targeting for advanced malignancies. Am J Cancer Res. 2023; 13(7):3257-3265. Moeller A, Kurzrock R, Botta GP, Adashek JJ, Patel H, Lee S, Pabla S, Nesline MK, Conroy J, Sicklick JK, Kato S. PMID: 37560003; PMCID: PMC10408490.
      View in: PubMed   Mentions: 4  
    30. Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies. JCO Precis Oncol. 2023 07; 7:e2200604. Shayeb AM, Kurzrock R, Adashek JJ, Kato S. PMID: 37437231; PMCID: PMC10581650.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    31. LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. Cancer Med. 2023 06; 12(12):13155-13166. Adashek JJ, Kato S, Nishizaki D, Miyashita H, De P, Lee S, Pabla S, Nesline M, Conroy JM, DePietro P, Lippman S, Kurzrock R. PMID: 37132280; PMCID: PMC10315766.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    32. Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population. Mol Oncol. 2023 09; 17(9):1844-1856. Rosenberg S, Ben Cohen G, Kato S, Okamura R, Lippman SM, Kurzrock R. PMID: 36694946; PMCID: PMC10483598.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. PMID: 36801912; PMCID: PMC9938883.
      View in: PubMed   Mentions: 4  
    34. Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy. Res Sq. 2023 Feb 16. Jou J, Kato S, Miyashita H, Thangathurai K, Pabla S, DePietro P, Nesline M, Conroy J, Rubin E, Eskander R, Kurzrock R. PMID: 36824739; PMCID: PMC9949233.
      View in: PubMed   Mentions:
    35. Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego. J Hematol Oncol Pharm. 2023 Feb; 13(1):19-25. Nikanjam M, Tinajero J, McGann M, Li J, Yang J, Shen F, Sicklick JK, Kato S, Capparelli E, Kurzrock R. PMID: 36998525; PMCID: PMC10054256.
      View in: PubMed   Mentions: 4  
    36. Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. NPJ Genom Med. 2023 Jan 20; 8(1):1. Shaya J, Kato S, Adashek JJ, Patel H, Fanta PT, Botta GP, Sicklick JK, Kurzrock R. PMID: 36670111; PMCID: PMC9860045.
      View in: PubMed   Mentions: 11  
    37. Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken. J Immunother Precis Oncol. 2022 Nov; 5(4):87-89. Nikanjam M, Kato S, Kurzrock R. PMID: 36483587; PMCID: PMC9714416.
      View in: PubMed   Mentions: 1  
    38. Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy. NPJ Precis Oncol. 2022 Sep 22; 6(1):67. Louie BH, Kato S, Kim KH, Lim HJ, Okamura R, Eskander RN, Botta G, Patel H, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 36138116; PMCID: PMC9500013.
      View in: PubMed   Mentions: 3  
    39. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022 09 12; 15(1):131. Nikanjam M, Kato S, Kurzrock R. PMID: 36096847; PMCID: PMC9465933.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansCells
    40. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022 Nov; 110:102461. Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, Kurzrock R. PMID: 36058143.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    41. Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response. J Hematol Oncol. 2022 08 28; 15(1):119. Persha HE, Kato S, De P, Adashek JJ, Sicklick JK, Subbiah V, Kurzrock R. PMID: 36031605; PMCID: PMC9420268.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    42. Carcinoma of unknown primary: Molecular tumor board-based therapy. CA Cancer J Clin. 2022 11; 72(6):510-523. Shreenivas AV, Kato S, Hu J, Skefos C, Sicklick J, Kurzrock R. PMID: 36006378; PMCID: PMC10180180.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. Targeting KRAS: Crossroads of Signaling and Immune Inhibition. J Immunother Precis Oncol. 2022 Aug; 5(3):68-78. Kato S, Fujiwara Y, Hong DS. PMID: 36034582; PMCID: PMC9390702.
      View in: PubMed   Mentions: 6  
    44. Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. Mol Oncol. 2022 07; 16(13):2575-2584. Louie BH, Kato S, Kim KH, Lim HJ, Lee S, Okamura R, Fanta PT, Kurzrock R. PMID: 35238467; PMCID: PMC9251876.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    45. Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting. Oncoimmunology. 2022; 11(1):2052410. Kato S, Li B, Adashek JJ, Cha SW, Bianchi-Frias D, Qian D, Kim L, So TW, Mitchell M, Kamei N, Hoiness R, Hoo J, Gray PN, Iyama T, Kashiwagi M, Lu HM, Kurzrock R. PMID: 35371621; PMCID: PMC8966985.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    46. Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies. NPJ Precis Oncol. 2022 Mar 28; 6(1):18. Gupta D, Kurzrock R, Lee S, Okamura R, Lim HJ, Kim KH, Sicklick JK, Kato S. PMID: 35347205; PMCID: PMC8960821.
      View in: PubMed   Mentions:
    47. Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. JCO Precis Oncol. 2022 01; 6:e2000508. Charo LM, Eskander RN, Sicklick J, Kim KH, Lim HJ, Okamura R, Lee S, Subramanian R, Schwab R, Shatsky R, Plaxe S, Kato S, Kurzrock R. PMID: 35005995; PMCID: PMC8769125.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    48. Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations. Clin Oncol Case Rep. 2022 Jan; 5(1). Nikanjam M, Kato S, Adashek JJ, Kurzrock R. PMID: 35403176; PMCID: PMC8994415.
      View in: PubMed   Mentions: 1  
    49. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. JCO Precis Oncol. 2021; 5. Kato S, Weipert C, Gumas S, Okamura R, Lee S, Sicklick JK, Saam J, Kurzrock R. PMID: 34778692; PMCID: PMC8585281.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    50. Hyperprogression in Gastric Cancer: Is MDM2 Amplification the Dark Horse? JCO Precis Oncol. 2021 11; 5:931-932. Dayyani F, Kato S, Kurzrock R. PMID: 34994620.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. Palbociclib as a Novel Therapy for Low-Grade Mucinous Carcinomatosis Peritonei of Appendiceal Origin. JCO Precis Oncol. 2021 11; 5:1069-1072. Childers BG, Sood D, Patel R, Mose ES, Hosseini M, Kato S, Baumgartner JM, Lowy AM. PMID: 34994628.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy. Mol Cancer Ther. 2021 12; 20(12):2341-2351. Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. PMID: 34642211; PMCID: PMC8643328.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    53. Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome Med. 2021 10 04; 13(1):155. Sicklick JK, Kato S, Okamura R, Patel H, Nikanjam M, Fanta PT, Hahn ME, De P, Williams C, Guido J, Solomon BM, McKay RR, Krie A, Boles SG, Ross JS, Lee JJ, Leyland-Jones B, Lippman SM, Kurzrock R. PMID: 34607609; PMCID: PMC8491393.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    54. Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity. Clin Cancer Res. 2021 10 01; 27(19):5334-5342. Sharma AK, de la Torre J, IJzerman NS, Sutton TL, Zhao B, Khan TM, Banerjee S, Cui C, Nguyen V, Alkhuziem M, Snaebjornsson P, van Boven H, Bruining A, Tang CM, Yoon H, De la Fuente A, Kato S, Patel H, Heinrich MC, Corless CL, Horgan S, Burgoyne AM, Fanta P, Mesirov JP, Blakely AM, Davis JL, Mayo SC, van Houdt WJ, Steeghs N, Sicklick JK. PMID: 34326133; PMCID: PMC8799780.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    55. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight. 2021 09 22; 6(18). Botta GP, Kato S, Patel H, Fanta P, Lee S, Okamura R, Kurzrock R. PMID: 34375311; PMCID: PMC8492298.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    56. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021 Nov; 100:102287. Mullen J, Kato S, Sicklick JK, Kurzrock R. PMID: 34619527.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimals
    57. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs. 2022 02; 40(1):99-105. Kato S, Adashek JJ, Subbiah V, Fu S, Sun M, Nguyen L, Brown EJ, Yap TA, Karp DD, Piha-Paul SA, Hong DS. PMID: 34468905.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    58. Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible. Mol Cancer Ther. 2021 11; 20(11):2274-2279. Jensen TJ, Goodman AM, Ellison CK, Holden KA, Kato S, Kim L, Daniels GA, Fitzgerald K, McCarthy E, Nakashe P, Mazloom AR, Almasri E, McLennan G, Grosu DS, Eisenberg M, Kurzrock R. PMID: 34465593; PMCID: PMC9398131.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    59. Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns. Oncologist. 2021 09; 26(9):787-796. Israel MA, Danziger N, McGregor KA, Murugesan K, Gjoerup O, Sokol ES, Tukachinsky H, Kurzrock R, Kato S, Sicklick JK, Nimeiri HS, Oxnard GR, Ross JS. PMID: 34080753; PMCID: PMC8417854.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    60. Did Everolimus Break the Rules? Clin Cancer Res. 2021 07 15; 27(14):3807-3808. Kato S, Cohen EEW. PMID: 33986025.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. Oncologist. 2021 07; 26(7):e1104-e1109. Kim JW, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer PM, Shyr Y, Ivy SP, LoRusso PM. PMID: 33742489; PMCID: PMC8265343.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    62. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021 May; 18(5):320. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. PMID: 33758378; PMCID: PMC7985918.
      View in: PubMed   Mentions: 2     Fields:    
    63. Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors. Eur J Cancer. 2021 05; 149:184-192. Kato S, Porter R, Okamura R, Lee S, Zelichov O, Tarcic G, Vidne M, Kurzrock R. PMID: 33865203.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    64. Missing the target in cancer therapy. Nat Cancer. 2021 04; 2:369-371. Adashek JJ, Goloubev A, Kato S, Kurzrock R. PMID: 34368781; PMCID: PMC8336921.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    65. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021 05; 18(5):313-319. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. PMID: 33723371; PMCID: PMC7957448.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCellsPHPublic Health
    66. KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. Oncologist. 2021 04; 26(4):e530-e536. Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander RN, Plaxe S, Parker B, Stites E, Kurzrock R. PMID: 33528846; PMCID: PMC8018312.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    67. High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. Int J Cancer. 2021 06 01; 148(11):2839-2847. Okamura R, Piccioni DE, Boichard A, Lee S, Jimenez RE, Sicklick JK, Kato S, Kurzrock R. PMID: 33497479; PMCID: PMC8048515.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    68. Cancer of Unknown Primary in the Molecular Era. Trends Cancer. 2021 05; 7(5):465-477. Kato S, Alsafar A, Walavalkar V, Hainsworth J, Kurzrock R. PMID: 33516660; PMCID: PMC8062281.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    69. Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. Clin Cancer Res. 2021 05 15; 27(10):2792-2797. Kato S, Adashek JJ, Shaya J, Okamura R, Jimenez RE, Lee S, Sicklick JK, Kurzrock R. PMID: 33472910; PMCID: PMC11005753.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    70. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. JCI Insight. 2021 01 11; 6(1). Kato S, Okamura R, Adashek JJ, Khalid N, Lee S, Nguyen V, Sicklick JK, Kurzrock R. PMID: 33427211; PMCID: PMC7821594.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    71. Immune profiling and immunotherapeutic targets in pancreatic cancer. Ann Transl Med. 2021 Jan; 9(2):119. Lenzo FL, Kato S, Pabla S, DePietro P, Nesline MK, Conroy JM, Burgher B, Glenn ST, Kuvshinoff B, Kurzrock R, Morrison C. PMID: 33569421; PMCID: PMC7867882.
      View in: PubMed   Mentions: 8  
    72. The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers. J Immunother Precis Oncol. 2021 May; 4(2):56-63. Gupta D, Kato S, Kurzrock R. PMID: 34337550; PMCID: PMC8320380.
      View in: PubMed   Mentions: 5  
    73. Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer. 2021 02 01; 127(3):391-402. Janku F, Sakamuri D, Kato S, Huang HJ, Call SG, Naing A, Holley VR, Patel SP, Amaria RN, Falchook GS, Piha-Paul SA, Zinner RG, Tsimberidou AM, Hong DS, Meric-Bernstam F. PMID: 33119140.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    74. Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. Oncologist. 2020 11; 25(11):e1803-e1806. Bohan SS, Sicklick JK, Kato S, Okamura R, Miller VA, Leyland-Jones B, Lippman SM, Kurzrock R. PMID: 32949172; PMCID: PMC7648352.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    75. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371; PMCID: PMC7532150.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    76. Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations-A Perspective from a Real-World Precision Medicine Cohort. Mol Cancer Ther. 2020 12; 19(12):2612-2620. Rosenberg S, Okamura R, Kato S, Soussi T, Kurzrock R. PMID: 32999047.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    77. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol. 2021 01; 15(1):67-79. Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R. PMID: 32881280; PMCID: PMC7782073.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    78. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int J Cancer. 2021 02 01; 148(3):702-712. Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK. PMID: 32700810; PMCID: PMC7739197.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    79. Letter responds to comment on "intention-to-treat analysis in precision oncology: A cautious interpretation". Eur J Cancer. 2020 10; 138:228. Sicklick J, Kato S, Kurzrock R. PMID: 32839070.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer. Front Oncol. 2020; 10:1312. Adashek JJ, Arroyo-Martinez Y, Menta AK, Kurzrock R, Kato S. PMID: 32850413; PMCID: PMC7418523.
      View in: PubMed   Mentions: 11  
    81. High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Mol Cancer Ther. 2020 10; 19(10):2139-2145. Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Mareboina M, Frampton GM, Fabrizio D, Sharabi AB, Kato S, Kurzrock R. PMID: 32747422; PMCID: PMC7541603.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    82. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. Cureus. 2020 Jul 02; 12(7):e8967. Cohen PR, Nikanjam M, Kato S, Goodman AM, Kurzrock R. PMID: 32766009; PMCID: PMC7398726.
      View in: PubMed   Mentions: 1  
    83. Transcriptomic silencing as a potential mechanism of treatment resistance. JCI Insight. 2020 06 04; 5(11). Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R. PMID: 32493840; PMCID: PMC7308055.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    84. Repurposing Interleukin-6 Inhibitors to Combat COVID-19. J Immunother Precis Oncol. 2020; 3(2):52-55. Kato S, Kurzrock R. PMID: 34169296; PMCID: PMC8221576.
      View in: PubMed   Mentions: 6  
    85. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020 05 19; 12(1):45. Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, Carter H, Kurzrock R. PMID: 32430031; PMCID: PMC7236948.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    86. Precision oncology: the intention-to-treat analysis fallacy. Eur J Cancer. 2020 07; 133:25-28. Sicklick JK, Kato S, Okamura R, Kurzrock R. PMID: 32422506; PMCID: PMC7786388.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    87. The paradox of cancer genes in non-malignant conditions: implications for precision medicine. Genome Med. 2020 02 17; 12(1):16. Adashek JJ, Kato S, Lippman SM, Kurzrock R. PMID: 32066498; PMCID: PMC7027240.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    88. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2020 02; 8(1). Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R. PMID: 32111729; PMCID: PMC7057434.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    89. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer. 2020 06 15; 146(12):3450-3460. Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R. PMID: 31782524; PMCID: PMC10200262.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    90. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019 12 04; 12(1):130. Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. PMID: 31801585; PMCID: PMC6894333.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    91. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? Oncologist. 2020 02; 25(2):94-98. Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. PMID: 32043794; PMCID: PMC7011624.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    92. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. Mol Cancer Ther. 2019 10; 18(10):1852-1862. Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R. PMID: 31320401.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    93. Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. Int J Cancer. 2020 01 15; 146(2):566-576. Mardinian K, Okamura R, Kato S, Kurzrock R. PMID: 31199507; PMCID: PMC6874714.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    94. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Mol Cancer Ther. 2019 06; 18(6):1149-1157. Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. PMID: 31015311; PMCID: PMC6548628.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    95. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019 05; 25(5):744-750. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. PMID: 31011206; PMCID: PMC6553618.
      View in: PubMed   Mentions: 262     Fields:    Translation:HumansCTClinical Trials
    96. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunol Res. 2019 06; 7(6):866-873. Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R. PMID: 31003990; PMCID: PMC6548620.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    97. Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. JCO Precis Oncol. 2019; 3. Kato S, Schwaederlé MC, Fanta PT, Okamura R, Leichman L, Lippman SM, Lanman RB, Raymond VM, Talasaz A, Kurzrock R. PMID: 31032472; PMCID: PMC6484865.
      View in: PubMed   Mentions: 29     Fields:    
    98. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. PMID: 31058253; PMCID: PMC6497417.
      View in: PubMed   Mentions: 37     Fields:    
    99. Identification of targets for prostate cancer immunotherapy. Prostate. 2019 04; 79(5):498-505. Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C. PMID: 30614027.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    100. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Mol Cancer Ther. 2019 02; 18(2):448-458. Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R. PMID: 30523049.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    101. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol. 2018; 2018. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. PMID: 30637364; PMCID: PMC6329466.
      View in: PubMed   Mentions: 137     Fields:    
    102. An avatar for precision cancer therapy. Nat Biotechnol. 2018 11 09; 36(11):1053-1055. Kato S, Kurzrock R. PMID: 30412185.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    103. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. PMID: 30383888; PMCID: PMC6340722.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    104. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018 12 15; 24(24):6248-6256. Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R. PMID: 30348637; PMCID: PMC6384095.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    105. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 09 01; 4(9):1237-1244. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. PMID: 29902298; PMCID: PMC6139049.
      View in: PubMed   Mentions: 143     Fields:    Translation:Humans
    106. JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biol Ther. 2018 08 03; 19(8):664-668. Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R. PMID: 29565699; PMCID: PMC6067874.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    107. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precis Oncol. 2018; 2018. Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R. PMID: 30148248; PMCID: PMC6106866.
      View in: PubMed   Mentions: 34     Fields:    
    108. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. PMID: 29695765; PMCID: PMC5988803.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    109. Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of Disease. Oncology (Williston Park). 2018 04 15; 32(4):150-1, 163. Kurzrock R, Kato S. PMID: 29684227.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    110. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018; 7(3):e1404217. Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 29399405; PMCID: PMC5790366.
      View in: PubMed   Mentions: 31     Fields:    
    111. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423. Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. PMID: 29047029; PMCID: PMC5908757.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    112. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. Oncologist. 2018 02; 23(2):171-178. Kato S, Kurasaki K, Ikeda S, Kurzrock R. PMID: 29038235; PMCID: PMC5813742.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    113. Genomics of Immunotherapy-Associated Hyperprogressors-Response. Clin Cancer Res. 2017 10 15; 23(20):6376. Kato S, Kurzrock R. PMID: 29030333.
      View in: PubMed   Mentions: 6     Fields:    
    114. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discov. 2017 12; 7(12):1464-1479. Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott KC, Cosset E, Lesperance J, Weis SM, Cheresh DA. PMID: 28893801; PMCID: PMC5718959.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    115. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386; PMCID: PMC5670009.
      View in: PubMed   Mentions: 1169     Fields:    Translation:HumansAnimalsCells
    116. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 10 01; 77(19):5419-5427. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. PMID: 28807936; PMCID: PMC5626633.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    117. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. Int J Mol Sci. 2017 Jul 31; 18(8). Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R. PMID: 28788102; PMCID: PMC5578053.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    118. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. PMID: 28729355; PMCID: PMC5902668.
      View in: PubMed   Mentions: 2     Fields:    
    119. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. J Natl Compr Canc Netw. 2017 07; 15(7):863-866. Kato S, Subbiah V, Kurzrock R. PMID: 28687573; PMCID: PMC6317845.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    120. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res. 2017 08 15; 77(16):4238-4246. Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R. PMID: 28642281; PMCID: PMC5729906.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    121. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 06; 22(6):631-637. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. PMID: 28550027; PMCID: PMC5469598.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    122. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Aug 01; 23(15):4242-4250. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. PMID: 28351930; PMCID: PMC5647162.
      View in: PubMed   Mentions: 460     Fields:    Translation:Humans
    123. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017 04 15; 23(8):1988-1997. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. PMID: 27683183.
      View in: PubMed   Mentions: 115     Fields:    Translation:Humans
    124. Genomic Landscape of Malignant Mesotheliomas. Mol Cancer Ther. 2016 10; 15(10):2498-2507. Kato S, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. PMID: 27507853.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    125. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 07; 15(7):1682-90. Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. PMID: 27196769.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    126. The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst. 2016 08; 108(8). Kato S, Lippman SM, Flaherty KT, Kurzrock R. PMID: 27059373; PMCID: PMC5017937.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    127. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. Oncotarget. 2015 Dec 01; 6(38):40642-54. Subbiah V, Wagner MJ, McGuire MF, Sarwari NM, Devarajan E, Lewis VO, Westin S, Kato S, Brown RE, Anderson P. PMID: 26510912; PMCID: PMC4747358.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    128. Genomic landscape of salivary gland tumors. Oncotarget. 2015 Sep 22; 6(28):25631-45. Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R. PMID: 26247885; PMCID: PMC4694855.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    129. A window-of-opportunity biomarker study of etodolac in resectable breast cancer. Cancer Med. 2015 Oct; 4(10):1583-8. Schwab RB, Kato S, Crain B, Pu M, Messer K, Weidner N, Blair SL, Wallace AM, Carson DA, Parker BA. PMID: 26275572; PMCID: PMC4618628.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    130. Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience. 2015; 2(7):646-58. Subbiah V, Bupathi M, Kato S, Livingston A, Slopis J, Anderson PM, Hong DS. PMID: 26328274; PMCID: PMC4549362.
      View in: PubMed   Mentions: 3  
    131. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience. 2015; 2(6):576-80. Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F. PMID: 26244164; PMCID: PMC4506360.
      View in: PubMed   Mentions: 17  
    132. Cell-free DNA as a novel marker in cancer therapy. Biomark Med. 2015; 9(7):703-12. Kato S, Janku F. PMID: 26174844.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    133. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle. 2015; 14(8):1252-9. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. PMID: 25695927; PMCID: PMC4614867.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    134. Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell. 2014 Aug 11; 30(3):295-308. Desgrosellier JS, Lesperance J, Seguin L, Gozo M, Kato S, Franovic A, Yebra M, Shattil SJ, Cheresh DA. PMID: 25117682; PMCID: PMC4147869.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    135. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. PMID: 24747441; PMCID: PMC4105198.
      View in: PubMed   Mentions: 221     Fields:    Translation:HumansAnimalsCells
    136. EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1. PLoS One. 2012; 7(5):e36753. Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, Schlaepfer DD, Cheresh DA. PMID: 22586492; PMCID: PMC3346745.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    Shumei's Networks
    Concepts (320)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (68)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California